Randomized Trial of Tenecteplase Versus Alteplase for Acute Ischemic Stroke - Tenecteplase Versus Alteplase for Acute Ischemic Stroke

Description:

Current guidelines recommend that intravenous alteplase (tPA) be administered for systemic fibrinolysis in patients presenting with acute ischemic stroke within 3 hours (Grade I) and within 4.5 hours (Grade IIC) of onset of symptoms. Tenecteplase (TNK) is a genetically modified version of tPA that has some pharmacokinetic benefits over tPA. The current phase II trial sought to compare outcomes in patients with acute ischemic stroke randomized to receive two low doses of TNK versus standar...